Papers by Carolyn Lam
19 results
- International Journal of Cardiology
Persistent C-reactive protein elevation and incident heart failure in adults at increased cardiovascular risk: A multinational electronic health record study
Cohort study of 64,743 peopleC-reactive protein - European Journal of Heart Failure
Mortality benefit and lifetime survival gains with vericiguat in HFrEF: Bayesian and actuarial analyses of the VICTOR trial
Randomised trial in peopleInterventions
- European Heart Journal
Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis
Trial in peopleInterventions - The Lancet Regional Health Western Pacific
The impact and evolution of environmental/occupational, behavioural, and metabolic risk factors on CVD burdens in the Asia-Pacific region from 1990 to 2023: a secondary analysis of the Global Burden of Disease Study 2023
Computational studyCardiovascular disease - Alzheimer's & Dementia
Plasma proteomics of cerebrovascular disease, cognitive decline, and clinical outcomes
Cohort study of 2,534 peopleCerebrovascular disease - Journal of the American College of Cardiology
Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF)
Randomised trial in 706 peopleHeart failure - Nephrology, Dialysis, Transplantation
Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD
Trial in peopleInterventions - ADA Scientific Sessions 2026 Abstract
The Addition of the AHA PREVENT Risk Model to NT-proBNP–Based Screening in Patients with Diabetes and Risk Factors for Heart Failure: An Exploratory Analysis of TARTAN-HF
Trial in peopleBiomarkers - AHA Scientific Sessions 2025 Abstract
Timing of Cardiovascular and Kidney Benefits with Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes
Trial in peopleInterventions - AHA Scientific Sessions 2025 Abstract
Interplay Between Heart Failure Progression, New-Onset Diabetes, and Finerenone: A FINEARTS-HF Analysis
Trial in peopleInterventions - AHA Scientific Sessions 2025 Abstract
Major Adverse Cardiovascular Events across the Spectrum of Cardio-Kidney-Metabolic Syndrome: A FINE-HEART Pooled Analysis
Trial in peopleInterventions - AHA Scientific Sessions 2025 Abstract
The HFpEF-ABA Algorithm and Finerenone in Chronic Kidney Disease with Type 2 Diabetes: A FINE-HEART Analysis
Trial in peopleBiomarkers - AHA Scientific Sessions 2025 Abstract
Finerenone Reduces Sudden Death across the Spectrum of Cardio-Kidney-Metabolism: the FINE-HEART Pooled Analysis
Trial in peopleInterventions - AHA Scientific Sessions 2025 Abstract
Finerenone and liver fibrosis assessed by fibrosis-4 (FIB-4) index in patients with heart failure and mildly reduced or preserved ejection fraction: Results from the FINEARTS-HF trial
Trial in peopleInterventions